Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.63 |
| ▸ | TUBB | P07437 | 1/20 | 0.63 |
| ▸ | YES1 | P07947 | 1/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.63 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.63 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.63 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.63 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.63 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.63 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.63 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.63 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.63 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9819049 | 0.81 | MAOB (0.65) | CYP19A1MAOBPBRM1BRD4CREBBP | |
| SCHEMBL9819043 | 0.81 | MAOB (0.65) | CYP19A1MAOBPBRM1BRD4CREBBP | |
| SCHEMBL9819050 | 0.80 | MAOB (0.63) | MAOBPBRM1 | |
| SCHEMBL9819102 | 0.80 | PBRM1 (0.77) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| SCHEMBL9818829 | 0.80 | PBRM1 (0.54) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| SCHEMBL17973709 | 0.80 | CYP19A1 (0.59) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| SCHEMBL22714605 | 0.80 | PBRM1 (0.50) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| SCHEMBL27984356 | 0.80 | TDP1 (0.61) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| Liquirtigenin SCHEMBL1071066 | 0.78 | CYP19A1 (1.00) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| Liquirtigenin SCHEMBL30352791 | 0.78 | CYP19A1 (1.00) | CYP19A1TUBB4ATUBBYES1TUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126835-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12516038-B2 | Inhibitors of antigen presentation by HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-06 | — | — | US | disclosed |
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| EP-4126835-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| US-20220160676-A1 | USE OF 3-O-SULFAMOYLOXY-7Beta-METHYL-D-HOMO-6-OXAESTRA-1,3,5(10),8(9)-TETRAEN-17A-ONE TO TREAT BREAST CANCER | ILIASOVA, NATALIA (RU) | 2022-05-26 | — | — | US | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10787428-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3712129-A1 | ALPHA, BETA-UNSATURATED AMIDE COMPOUND | Kyowa Kirin Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3401309-A1 | a, ß UNSATURATED AMIDE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-11-14 | — | — | EP | disclosed |
| CN-108430972-A | α, β unsaturated acyl amine compounds | 协和发酵麒麟株式会社 | 2018-08-21 | — | — | CN | disclosed |
| WO-2014146553-A1 | FLAVONOID DERIVATIVES AND USE THEREOF | 江苏恩华药业股份有限公司 (CN) | 2014-09-25 | — | — | WO | disclosed |
| EP-0230475-B1 | NOVEL UREA DERIVATIVES, PROCESSES FOR PRODUCTION THEREOF AND HERBICIDE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4838924-A | NONPHYTOTOXIC | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, RXRA | CYP19A1 474/4885TUBB4A 1772/4885TUBB 1583/4885 |
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | CYP19A1 404/4885TUBB4A 1869/4885TUBB 1751/4885 |
| US-10787428-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | CYP19A1 269/4885TUBB4A 2377/4885TUBB 2402/4885 |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | CYP19A1 3518/4885TUBB4A 3889/4885TUBB 3077/4885 |
| US-20220160676-A1 | USE OF 3-O-SULFAMOYLOXY-7Beta-METHYL-D-HOMO-6-OXAESTRA-1,3,5(10),8(9)-TETRAEN-17A-ONE TO TREAT BREAST CANCER | SULT1E1, BRCA1, CYP19A1 | CYP19A1 3/4885TUBB4A 443/4885TUBB 435/4885 |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | CYP19A1 302/4885TUBB4A 2172/4885TUBB 2081/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | CYP19A1 269/4885TUBB4A 2377/4885TUBB 2402/4885 |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | CYP19A1 302/4885TUBB4A 2172/4885TUBB 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.